Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates
October 29, 2020 7:00 AM EDTPhase 3 study of COVID-19 vaccine candidate (mRNA-1273) fully enrolled with 30,000 participants, including 37% from diverse communities and 42% at high-risk of severe disease (>65 years or co-morbid risk factors)
Positive interim data from Phase 2 study of CMV vaccine candidate (mRNA-1647) announced during R&D Day; pivotal Phase 3 trial expected to begin in 2021
Received $1.1 billion of customer deposits for supply of mRNA-1273 in Q3 2020, recorded as deferred revenue
CAMBRIDGE, Mass.--(BUSINESS... More
